Scientific Corner

New Scales and Scores by EAN Scientific Panel on Higher Cortical Functions are available online now!

The Bulgarian Society of Neurology has submitted its guidelines, which are now available for EAN Members in the Guideline Reference Center.

The French Society of Neurology has submitted its guidelines, which are now available for EAN Members in the Guideline Reference Center.

The two European Reference Networks (ERNs) for Rare Neurological Diseases and Rare Neuromuscular Diseases (ERN-RND and ERN-EuroNMD) are launching a new joint educational program in collaboration with the European Academy of Neurology.

The  Portuguese Neurological Society has submitted its guidelines, which are now available for EAN Members in the Guideline Reference Center.

Clinical practice guidelines are a bridge between scientific evidence and real-world practice. This is the main reason why I decided to advance my background experience (in epidemiology, systematic reviews and meta-analyses), by working on guidelines. Because Neurology is my main… Continue Reading

Production of European standards of diagnosis, treatment and care within the various subfields of neurology, is one of the most important aims of EAN. EAN has therefore set-up a Guideline Production Group (GPG), to provide scientific assistance to active task forces and to oversee the work flow.

Trigeminal neuralgia (TN) is an extremely painful condition which can be difficult to diagnose and treat.

28 February 2019 is the twelfth international Rare Disease Day coordinated by EURORDIS. On and around this day hundreds of patient organisations from countries and regions all over the world will hold awareness-raising activities. The theme for Rare Disease Day 2019 is 'Bridging health and social care' focusing on bridging the gaps in the coordination between medical, social and support services in order to tackle the challenges that people living with a rare disease and their families around the world face every day.

How do neurology and palliative care services collaborate across Europe? There is increasing interest in providing palliative care for people with progressive neurological disease but the full extent of the relationship is not known. The EAN Palliative Care Specialty Panel… Continue Reading

  Vienna, 12-13 October 2018: First recommendation meeting of the EAN ALS guideline panel. ALS is a disease with a very high unmet medical need. There are only limited options for disease-modifying pharmacotherapy. The cornerstone of the management remains multidisciplinary… Continue Reading

Recently, EAN held elections of the Scientific Panel Management groups. All Panel Members - institutional that are nominated by a national society, and individual - were invited to send in their applications. The Scientific Committee received altogether 163 applications, from 30 different countries (59 female and 104 male applicants).

Scientific plagiarism is defined as using or closely imitating scientific content from an original author without clear reference and/or authorization. Plagiarism can be complete or partial, in the original or translated version or limited to paraphrases of the original text. A textual repetition of one’s own work in subsequent submissions is considered self-plagiarism and should be avoided or at least accompanied by proper referencing to one’s prior work.

Antonio Federico (AF): On January 29-30, there has been in Tubingen the Kick-Off Meeting of the EU Project Solve-RD. You and Prof. Olaf Riess are coordinating this project. Can you summarize the aim and the activities of this important project? Holm Graessner (HG): To obtain a molecularly confirmed diagnosis remains one of the largest challenges for rare disease patients. To jointly tackle this challenge a core group of four European Reference Networks including the European Reference Network for Rare Neurological Diseases has motivated, designed and put together the Solve-RD project which is the first ERN based H2020 funded research project. Solve-RD brings together 21 partners from 10 countries which will be running from 2018 to 2022.